Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Taylor G. Sandison, MD
Sponsor: Elion Therapeutics, Chief Medical Officer
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Az Sint-Jan Brugge
Bruges, Belgium
Recruiting - Universite Libre de Bruxelles (ulb) - Institut Jules Bordet
Brussels, Belgium
Recruiting - Uz Leuven
Leuven, Belgium
Recruiting
- Juravinski Hospital
Hamilton, Ontario, Canada
Recruiting
- Centre Hospitalier D'Argenteuil
Argenteuil, France
Recruiting - Ap-Hp Hopital Henri Modor
Créteil, France
Recruiting
- Istituto Europeo Di Oncologia
Milan, Italy
Recruiting - Fondazione Policlinico Universitario A. Gemelli Irccs- Universita Cattolica del Sacro Cuore
Roma, Italy
Recruiting
- Hospital Clinic Barcelona
Barcelona, Spain
Recruiting - Hospital Universitario Vall D'Hebron
Barcelona, Spain
Recruiting - Hospital del Mar
Barcelona, Spain
Recruiting - Hospital Universitario Puerta de Hierro
Majadahonda, Spain
Recruiting - Hospital Clinico Universitario de Salamanca
Salamanca, Spain
Recruiting
- U. of Alabama at Birmingham
Birmingham, Alabama, United States
Recruiting - Uc Davis Medical Center
Sacramento, California, United States
Recruiting - Augusta University Medical Center
Augusta, Georgia, United States
Recruiting - Massachusetts General Hospital
Boston, Massachusetts, United States
Recruiting - U. of Michigan
Ann Arbor, Michigan, United States
Recruiting - Washington U.
St Louis, Missouri, United States
Recruiting - U. of Texas, Md Anderson
Houston, Texas, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 13 Feb 2026
- Primary completion
- 31 Dec 2026
- Completion
- 31 Dec 2026
- Last update posted
- 5 Aug 2026
- Registered enrollment
- 60
- Registry id
- NCT07215273
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.